Alnylam draws on patient artist’s striking depictions of life with a rare genetic disease in new ad campaign
College student Amalia had just begun her freshman year when she came down with flu-like symptoms that worsened into debilitating stomach pain and eventually an inability to eat or drink. While doctors struggled to determine the cause as months wore on, Amalia turned to art and painting to express her pain and hopeless feelings.
She was eventually diagnosed with the rare genetic disease acute hepatic porphyria (AHP) — and now both Amalia and her art are featured in Alnylam Pharmaceutical’s latest campaign for its med Givlaari, approved in 2019 to treat AHP in adults.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
